Blogs

Immune Monitor - March 2026

By SITC Communications posted 4 days ago
Be the first person to like this.
A Message from the President One of the most impactful ways the Forward Fund supports early-career investigators is through its fellowship program . These awards provide critical funding and mentorship to help launch independent research careers in immuno-oncology. Since 2014, these fellowships have provided $6.32 million in fellowship awards. Letters of intent for fellowship applications are due April 15 , and I encourage eligible members to consider applying and to share this opportunity with trainees and colleagues. We are also excited to announce that applications are open for the 2026 Women in Cancer Immunotherapy Network Leadership Institute ...
0 comments

SITC Publishes Renal Cell Carcinoma Clinical Practice Guideline version 3.0

By Thomas Martin posted 6 days ago
Be the first person to like this.
The Society for Immunotherapy of Cancer (SITC) is pleased to announce the publication of a guideline update, “Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0” in the Journal for ImmunoTherapy of Cancer ( JITC ). The RCC treatment landscape has evolved considerably since the previous publication of SITC’s RCC guideline in 2019. Immune checkpoint inhibitor (ICI) therapy is now approved in the adjuvant setting and is a treatment option for patients with resectable RCC at high risk for recurrence. Furthermore, additional ICI-based combination therapies have since ...
0 comments

SITC Publishes Expert Insights on ICI-Related irAE Survivorship Care

By JITC Publications posted 8 days ago
Be the first person to like this.
The Society for Immunotherapy of Cancer is pleased to announce the publication of a new article, “ Where is the data? Delayed and chronic irAE surveillance and management after cessation of ICIs: Expert insights from SITC on survivorship care and the need for long-term data ” in the Journal for ImmunoTherapy of Cancer . Over the past two decades, immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, providing durable disease control for many patients. Thanks to an increasing number of ICIs approved for new diseases and in earlier disease states, there is a growing population of survivors with a history of ICI treatment. Unfortunately, these ...
0 comments

Oncology News Burst from the FDA: FDA Approves Nivolumab with Chemotherapy for Previously Untreated Hodgkin Lymphoma

By SITC Communications posted 8 days ago
Be the first person to like this.
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position on the safety or efficacy of the product or therapy described. ...
0 comments

JITC Digest March 2026

By JITC Publications posted 13 days ago
Be the first person to like this.
INSIDE THIS ISSUE: Letter from the Editor| JITC Editor Picks|Special Series: SITC 40 th Anniversary| Popular Archive Articles Letter from the Editor Hello JITC Readers, We are quite fortunate to have several philanthropic agencies supporting and promoting the development of novel therapies in the IO space. These include the recent fundraiser for the Emily Whitehead Foundation that I was privileged to attend as part of the G-Rex® Grant Tour at The Franklin Institute in Philadelphia last month. The Foundation provides counseling and support to families preparing for cell therapy, while promoting ...
0 comments

SITC on Capitol Hill!

By SITC Advocacy posted 20 days ago
Be the first person to like this.
On March 4, 2026, SITC proudly joined One Voice Against Cancer's (OVAC's) 2026 Lobby Day in Washington, DC, with SITC volunteer Dr. Emily Hopewell, advocating for increased funding for the National Institutes of Health (NIH), National Cancer Institute (NCI), and the Centers for Disease Control and Prevention (CDC). We had the opportunity to meet with numerous congressional offices, including Senator Tammy Baldwin and Representative Gwen Moore, to highlight the impact of cancer immunotherapy. A heartfelt thank you to our dedicated volunteers and partner organizations for raising your voices and shining a spotlight on the promise of cancer research. Your ...
0 comments

Announcing the publication of “Advancing Cell Therapies for Solid Tumors: A Pathway to Overcome Biological, Operational, and Regulatory Hurdles” manuscript

By SITC Advocacy posted 21 days ago
Be the first person to like this.
The Society for Immunotherapy of Cancer (SITC) and the American Society for Transplantation and Cellular Therapy (ASTCT) are pleased to announce the publication of a comprehensive manuscript, “Advancing Cell Therapies for Solid Tumors: A Pathway to Overcome Biological, Operational, and Regulatory Hurdles” in Transplantation and Cellular Therapy (JTCT). The new manuscript, developed from the 2025 Summit on Advancing Cell Therapy for Solid Tumors, outlines a framework for advancing cellular therapy development in solid tumors. SITC and ASTCT experts addressed key scientific and practical challenges shaping cellular therapy. Read the newly published manuscript ...
0 comments

Oncology News Burst from the FDA: FDA Approves Teclistamab in Combination with Daratumumab Hyaluronidase-fihj for Relapsed or Refractory Multiple Myeloma

By SITC Communications posted 25 days ago
Be the first person to like this.
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position on the safety or efficacy of the product or therapy described. ...
0 comments

Immune Monitor - February 2026

By SITC Communications posted 02-26-2026
Be the first person to like this.
A Message from the President The Journal for ImmunoTherapy of Cancer ( JITC ) has long been integral to SITC’s mission to advance the science and application of cancer immunotherapy . As the field continues to evolve rapidly, JITC serves as a trusted global platform for advancing scientific understanding across the entire translational research spectrum from basic tumor immunology to clinical practice. My connection to JITC is long-standing and deeply personal. I first became involved with the journal as a founding editor and, over nearly a decade, have had the privilege of serving as a Section Editor, Deputy Editor-in-Chief and, for a time, Interim ...
0 comments

JITC Digest February 2026

By JITC Publications posted 02-18-2026
Be the first person to like this.
INSIDE THIS ISSUE: Letter from the Editor| JITC Editor Picks| JITC Peer Review Mentorship Program| Popular Archive Articles Letter from the Editor Hello JITC Readers, This has been a busy month for the JITC editors, as each of the individual sections have been meeting to discuss the strategic vision for the journal and make plans to accomplish these goals. February is also National Cancer Prevention Month. A good start to the month would be to read Olja Finn’s JITC commentary, “ Opportunity knocking: shared tumor-associated antigen vaccines against global cancer pandemic ,” just published and focused ...
0 comments

Immune Monitor - January 2026

By SITC Communications posted 01-29-2026
Be the first person to like this.
A Message from the President As we begin 2026, I’m pleased to share that SITC’s 2025 Year in Review is now live. It reflects a year defined by both complexity and innovation, and highlights the scientific progress, educational growth, and collective impact made possible by our global community. I invite you to explore the Year in Review website and read my full letter below, where I reflect on our shared accomplishments and the momentum carrying us forward. Read the SITC Year in Review >> Remembering Dr. Ernest Borden SITC honors the memory of Dr. Ernest Borden, who passed away on Jan. 18, 2026. We are deeply grateful ...
0 comments

Call for Comment: SITC Acute Leukemia CPG v2.0 Until Feb. 16

By Chuck Kolawole posted 01-28-2026
Be the first person to like this.
MANUSCRIPT TITLE: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia v2.0 Draft Manuscript Summary The Society for Immunotherapy of Cancer (SITC) Acute Leukemia (AL) Immunotherapy Guideline Expert Panel is pleased to invite public comment on the draft clinical practice guideline (CPG) “Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia v2.0,” an update to the society’s 2020 CPG for this disease setting. The new AL manuscript is part of the broader catalogue of SITC Cancer ...
0 comments

JITC Digest January 2026

By JITC Publications posted 01-21-2026
Be the first person to like this.
INSIDE THIS ISSUE: Letter from the Editor| JITC Editor Picks|Thank You to JITC Reviewers| Popular Archive Articles Letter from the Editor Hello JITC Readers, Indeed, “ it takes a village “ for JITC to receive, review, improve and then promote the important work in immuno-oncology that we have the privilege to consider and develop in our Journal . We express our gratitude to all our Section and Associate Editors as we head into this New Year. I would like to welcome the new editors joining us and also send a sincere thank you to those whose terms concluded at the end of last ...
0 comments

Immune Monitor - December 2025

By SITC Communications posted 01-06-2026
Be the first person to like this.
A Message from the President As 2025 draws to a close, I am humbled by the resilience of our community. Throughout the year, many of us faced disruption in our clinics and labs with the uncertain and shifting funding paradigm. However, thanks to each of you, 2025 was a year of remarkable progress for our community. Like our members, SITC’s leadership remained steadfast and future focused . At the biotech strategic meeting at the NYSE, we explored opportunities to advance TCEs, bispecifics and in vivo CAR T approaches. Our summit on expanding access to cell therapies for solid tumors brought together experts to examine pathways into the community ...
0 comments

JITC Digest December 2025

By JITC Publications posted 12-17-2025
Be the first person to like this.
INSIDE THIS ISSUE: Letter from the Editor| JITC Editor Picks| Popular Archive Articles Letter from the Editor Hello JITC Readers, The recent award of the Nobel Prize in Physiology or Medicine to Mary Brunkow, Fred Ramdsell and Shimon Sakaguchi (which I watched on a LinkedIn broadcast) highlighted for me the importance of fundamental research. This goes back to the spontaneous mutation observed by William and Liane Russell in male mice at the Oak Ridge National Laboratory in eastern Tennessee that had previously been part of the Manhattan Project in 1943. These mice were continuously bred and maintained ...
0 comments

2025 ESMO IO Scientific Highlights

By Keegan Mager posted 12-12-2025
Be the first person to like this.
We are pleased to present highlights of the latest advances in immunotherapy emerging from the ESMO Immuno-Oncology Congress 2025, Dec. 10–11, 2025. Clinical and translational studies of neoadjuvant pembroluzmab and lenvatinib in patients with resectable early-stage lung cancer LBA1. Neoadjuvant induction with pembrolizumab (Pembro) plus lenvatinib (Len) in resectable early-stage NSCLC impacts the tumor microenvironment (TME): Clinical results including multi-omic deconvolution of the TME from the INNWOP01 study Andreas Pircher (Innsbruck Medical University, Innsbruck, Austria) presented results from the INNWOP01 study a single-center ...
0 comments

SITC Hosts "AI, Upcoming Technologies, and Potential Applications: Computational Science in Immuno-oncology" Webinar

By SITC Advocacy posted 12-10-2025
Be the first person to like this.
On December 2, 2025, the Society for Immunotherapy of Cancer (SITC) in partnership with the National Cancer Institute (NCI) held the tenth computational immuno-oncology webinar of series 5. This webinar discussed patient burden dynamics, serum, tumor genomic, and functional profiles contain valuable insights for cancer research. It demonstrated how AI, computational, and mathematical driven approaches can integrate these profiles to model the tumor-microenvironment interactions, discover novel IO targets and biotherapeutics, predict patient responses to immunotherapy, elucidate mechanisms of IO resistance, and develop therapies that exploit drug dosing and sequencing. ...
0 comments

NEW! Myeloid Cells in Immuno-Oncology

By JITC Publications posted 12-02-2025
Be the first person to like this.
Edited by Dmitry I. Gabrilovich, MD, PhD; Jennifer L. Guerriero, PhD; and Judith A. Varner, PhD The special JITC series, Myeloid Cells in Immuno-oncology, developed in collaboration with The Myeloid Network , builds on the momentum and enthusiasm generated by prior jointly sponsored SITC Annual Meeting pre-conference workshops and programs focused on elucidating the mechanisms and therapeutic targeting of myeloid cells in immuno-oncology. This series features expert, in-depth reviews on the roles of myeloid cells and their metabolic regulation in cancer immunotherapy. Further, the series presents multiple expert perspectives on controversial and ...
0 comments

Oncology News Burst from the FDA: FDA Approves Durvalumab with FLOT for Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

By SITC Communications posted 12-01-2025
Be the first person to like this.
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position on the safety or efficacy of the product or therapy described. ...
0 comments

Immune Monitor - November 2025

By SITC Communications posted 11-25-2025
Be the first person to like this.
A Message from the President SITC’s 40 th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2025) marked a milestone for our society. We are deeply grateful to everyone who contributed to its success, including attendees, faculty, supporters, staff and volunteers. The meeting convened the immuno-oncology community in National Harbor, MD and virtually for several days of meaningful dialogue and groundbreaking science. With more than 1,300 abstracts presented, this year’s program demonstrated the continued momentum driving the field forward. Jennifer Wargo, MD, MMSc , delivered an excellent keynote address on the role of the microbiome in ...
0 comments